“I think we can see there are a lot of ways where openness can be powerful. What’s necessary is to help facilitate openness and reduce the barriers to sharing medical information.” – Ben Heywood
PatientsLikeMe Co-Founder Ben Heywood has blogged previously about openness and sharing – and how important they are for patients. In this edition of PatientsLikeMeOnCall, he talks about the progress we’ve made in achieving openness within the healthcare industry and his vision for the expansion of the patient voice.
How can we put patients back at the center of healthcare? What barriers do we need to break through so that patients like you can openly share your health information? Ben answers these questions and more in the fourth and final episode of our “A Look Ahead” podcast series.
Tune in to Ben’s full interview here:
Did you miss any of the first three episodes? Find them on our blog or iTunes page.
- Filed Under: ALS, Chronic Fatigue Syndrome, Conditions, Epilepsy, Fibromyalgia, HIV/AIDS, Mental Health, Multiple Sclerosis, Organ Transplants, Parkinson's Disease, Patient Experiences, Rare Diseases
- Tags: A Look Ahead, Ben Heywood, interview, Openness, patient voice, PatientsLikeMeOnCall, podcast
“What are the things that affect a patient’s safety? It’s everything – it’s not just whether the drug is good or bad, it’s the whole process.” –Jamie Heywood
Why does the healthcare industry need to shift from drug safety to patient safety? PatientsLikeMe Co-Founder and Chairman Jamie Heywood explains his view in this week’s edition of our podcast series entitled “A Look Ahead.”
No stranger to this topic, Jamie has written about patient safety on our blog before. “By using structured data collection tools within the PatientsLikeMe platform, overseen by a drug safety professional, industry partners can improve patient safety,” he wrote.
In this edition of PatientsLikeMeOnCallTM, Jamie discusses the difference between drug safety and patient safety, why it is so important for the healthcare system to adapt more to patient safety and what this shift would mean for the future of healthcare. He also makes the case for why pharmaceutical manufacturers need to follow up on any drug safety events when a new treatment has been developed.
To hear more, listen to Jamie’s full interview:
- Filed Under: ALS, Chronic Fatigue Syndrome, Conditions, Epilepsy, Fibromyalgia, HIV/AIDS, Mental Health, Multiple Sclerosis, Organ Transplants, Parkinson's Disease, Rare Diseases
- Tags: jamie heywood, patient safety, PatientsLikeMeOnCall, podcast